Key points are not available for this paper at this time.
Introduction 10 years, age 30-67 years, with no history of CVD were examined by carotid ultrasound and coronary artery calcium (CAC) score. Twelve patients were recognized as high-risk defined as CAC score 400 and/or presence of ≥2 carotid plaques. Patients were subsequently examined by coronary angiography and OCT. Results: Mean age was 64.5±1.8 years, T1D duration 36±11.5 years, HbA1c 7.5±0.8 % and baseline LDL 88.9±21.3 mg/dl. Thin-cap fibroatheroma (TCFA Figure-A) was identified in 7/12 (58.3%) patients and very high-risk plaque (TCFA with lumen area 3.5 mm2 B, lipid arch 180° and macrophages C) was present in 4/12 (33.3%) patients. We saw intraluminal thrombus D and cholesterol crystal E in 3/12 (25%) patients. A strong correlation between OCT stenosis and CAC score at the left anterior descending artery (Pearson’s r=0.75, p=0.005) was identified. Conclusion: Our study showed that asymptomatic T1D patients with high CAC score and carotid plaques had very severe OCT findings. We observed a significant proportion of high-risk lesions potentially associated with plaque rupture and risk of CV death. Disclosure M. Dubsky: None. R. Roland: None. N. Marhefková: None. P. Wohlfahrt: None. P. Novodvorsky: Speaker's Bureau; Sanofi, Boehringer-Ingelheim. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Novo Nordisk A/S. Research Support; Sanofi. Speaker's Bureau; Abbott, Medtronic, Berlin-Chemie AG, Viatris Inc., Novartis AG. V. Karmazin: None. M. Haluzik: Advisory Panel; Sanofi, Novo Nordisk, Eli Lilly and Company, AstraZeneca, Bayer Inc., Johnson Merck Sanofi. Speaker's Bureau; Sanofi, Novo Nordisk. M. Pazdernik: None. Funding Supported by the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104) - Funded by the European Union - Next Generation EU.
Dubský et al. (Fri,) studied this question.